SCHEMBL4777158

SCHEMBL4777158

CN(C)S(=O)(=O)c1ccc(SC2CCN(C(=O)C(F)(F)F)CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 1/20 0.42
NPY2R P49146 3/20 0.41
ALDH1A1 P00352 4/20 0.40
LMNA P02545 3/20 0.39
ADRB2 P07550 1/20 0.39
ADRB3 P13945 1/20 0.39
TSPO P30536 1/20 0.39
TMEM97 Q5BJF2 1/20 0.39
GPR65 Q8IYL9 1/20 0.39
HTR2A P28223 2/20 0.38
HTR2C P28335 1/20 0.38
ABCC9 O60706 1/20 0.38
ABCC8 Q09428 1/20 0.38
KCNJ11 Q14654 1/20 0.38
KCNJ8 Q15842 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4778086 0.89 HTR2A (0.37) SLC9A1NPY2RALDH1A1HTR2AHTR2C
SCHEMBL4775686 0.87 HPGD (0.46) NPY2RALDH1A1LMNAABCC9ABCC8
SCHEMBL4776586 0.84 KDM1A (0.39) KDM1AKMT2A
SCHEMBL4775636 0.81 SLC9A1 (0.44) SLC9A1NPY2RALDH1A1LMNAADRB2
SCHEMBL4778050 0.81 TSHR (0.47) ALDH1A1LMNAABCC9ABCC8KCNJ11
SCHEMBL14082453 0.79 KDM1A (0.43) SLC9A1KDM1ATDP1KMT2A
SCHEMBL4773959 0.78 KDM1A (0.53) ALDH1A1SMN1; SMN2KDM1AKMT2A
SCHEMBL4770310 0.71 HTR2A (0.39) SLC9A1NPY2RALDH1A1HTR2AHTR2C
SCHEMBL6297841 0.70 ESR1 (0.61) ALDH1A1HTR2CMAPTHTTMEN1
SCHEMBL4776446 0.69 HPGD (0.48) NPY2RALDH1A1LMNAABCC9ABCC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348324-B2 Cyclic amine compounds as CCR5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-25 US disclosed
EP-1886994-A1 Cyclic amine compounds as CCR5 antagonists Takeda Pharmaceutical Company Limited (JP) 2008-02-13 EP disclosed
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists TOBIRA THERAPEUTICS, INC. 2003-06-19 US disclosed
US-6562978-B1 N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists CCR5, CCR1, CCR3 SLC9A1 255/4885NPY2R 398/4885ALDH1A1 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.